{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:45:08Z","timestamp":1787010308478,"version":"build-2736575974"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Magnetic resonance cholangiopancreatography (MRCP) is used in the diagnosis and management of primary sclerosing cholangitis (PSC). However, MRCP is subjective, and guidelines state that there is insufficient evidence to recommend MRCP as a prognostic tool. EASL-PSC guidelines have identified quantitative MRCP (MRCP+) as having promising utility for risk assessment and prediction of clinical outcomes. We conducted a systematic review to determine the clinical utility of MRCP+ metrics for the management of patients with PSC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We systematically searched PubMed and MEDLINE for cohort studies reporting on MRCP+ metrics associated with risk prediction, clinical outcomes, and disease progression published between January 2019 and May 2024. Studies reporting on adults with diagnosed PSC with paired MRCP were selected. There were no limitations on the type of study (retrospective\/prospective). Studies reporting on only qualitative assessment of MRCP were excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Six manuscripts with 512 subjects met the study criteria. For risk prediction and disease progression, 4 articles reported 21 unique MRCP+ metrics, which were significantly associated with the Amsterdam-Oxford model and the MAYO risk score. MRCP+ metrics had AUC ranging 0.65 to 0.87 and hazard ratios ranging 0.96 to 17.79 for the prediction of adverse outcomes, including liver transplantation, death, hepatic decompensation, biliary complications, and cholangiocarcinoma. Associations between biochemical markers of liver function (alkaline phosphatase, bilirubin, aspartate aminotransferase, gamma glutamyl transferase, and albumin) ranged -0.42\u2264\n                      <jats:italic toggle=\"yes\">R<\/jats:italic>\n                      \u22640.48.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>MRCP+ metrics have clinical utility to support patient management alongside addressing key gaps, including standardising MRCP assessment, early detection of disease, and quantification of risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rct.0000000000001835","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T11:00:23Z","timestamp":1767610823000},"page":"365-375","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["The Prognostic Utility of Quantitative Magnetic Resonance Cholangiopancreatography in Patients With PSC: A Systematic Review With Structured Evidence Synthesis"],"prefix":"10.1097","volume":"50","author":[{"given":"Raj","family":"Vuppalanchi","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatih","family":"Akisik","sequence":"additional","affiliation":[{"name":"Department of Radiology, Indiana University School of Medicine, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Pansini","sequence":"additional","affiliation":[{"name":"Clinica Di Radiologia EOC, Istituto Di Imaging Della Svizzera Italiana (IIMSI), Ente Ospedaliero Cantonale, Lugano, Switzerland"},{"name":"John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma L.","family":"Culver","sequence":"additional","affiliation":[{"name":"Translational Gastroenterology and Liver Unit, John Radcliffe Hospital"},{"name":"Nuffield Department of Medicine, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Pratt","sequence":"additional","affiliation":[{"name":"Massachusetts General Research Institute, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0351-2063","authenticated-orcid":false,"given":"Elizabeth","family":"Shumbayawonda","sequence":"additional","affiliation":[{"name":"Perspectum Ltd, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukesh","family":"Harisinghani","sequence":"additional","affiliation":[{"name":"Department of Radiology, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5]]},"reference":[{"key":"R1-20260605","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1136\/gutjnl-2018-317993","article-title":"British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis","volume":"68","author":"Chapman","year":"2019","journal-title":"Gut"},{"key":"R2-20260605","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jhep.2022.05.011","article-title":"EASL Clinical Practice Guidelines on sclerosing cholangitis","volume":"77","year":"2022","journal-title":"J Hepatol"},{"key":"R3-20260605","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.cgh.2020.05.064","article-title":"Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States","volume":"19","author":"Younossi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R4-20260605","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/hep.32771","article-title":"AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma","volume":"77","author":"Bowlus","year":"2023","journal-title":"Hepatology"},{"key":"R5-20260605","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1111\/apt.17944","article-title":"Quantitative MRCP and metrics of bile duct disease over time in patients with primary sclerosing cholangitis: a prospective study","volume":"59","author":"Trivedi","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"R6-20260605","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0025-6196(11)64614-4","article-title":"A revised natural history model for primary sclerosing cholangitis","volume":"75","author":"Kim","year":"2000","journal-title":"Mayo Clin Proc"},{"key":"R7-20260605","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jhep.2019.06.012","article-title":"Validation, clinical utility and limitations of the Amsterdam-Oxford model for primary sclerosing cholangitis","volume":"71","author":"Goet","year":"2019","journal-title":"J Hepatol"},{"key":"R8-20260605","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1016\/j.cgh.2019.03.013","article-title":"Simple magnetic resonance scores associate with outcomes of patients with primary sclerosing cholangitis","volume":"17","author":"Lemoinne","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R9-20260605","doi-asserted-by":"crossref","first-page":"427","DOI":"10.7326\/0003-4819-144-6-200603210-00010","article-title":"Evaluation of the quality of prognosis studies in systematic reviews","volume":"144","author":"Hayden","year":"2006","journal-title":"Ann Intern Med"},{"key":"R10-20260605","doi-asserted-by":"crossref","first-page":"100577","DOI":"10.1016\/j.jhepr.2022.100577","article-title":"Quantitative magnetic resonance cholangiopancreatography metrics are associated with disease severity and outcomes in people with primary sclerosing cholangitis","volume":"4","author":"Cazzagon","year":"2022","journal-title":"JHEP Rep"},{"key":"R11-20260605","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.dld.2022.10.015","article-title":"A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis","volume":"55","author":"Cristoferi","year":"2023","journal-title":"Dig Liver Dis"},{"key":"R12-20260605","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00330-021-08142-y","article-title":"Evaluation of quantitative MRCP (MRCP+) for risk stratification of primary sclerosing cholangitis: comparison with morphological MRCP, MR elastography, and biochemical risk scores","volume":"32","author":"Ismail","year":"2022","journal-title":"Eur Radiol"},{"key":"R13-20260605","doi-asserted-by":"crossref","first-page":"100834","DOI":"10.1016\/j.jhepr.2023.100834","article-title":"A composite score using quantitative magnetic resonance cholangiopancreatography predicts clinical outcomes in primary sclerosing cholangitis","volume":"5","author":"Vuppalanchi","year":"2023","journal-title":"JHEP Rep"},{"key":"R14-20260605","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/hep4.1860","article-title":"A quantitative magnetic resonance cholangiopancreatography metric of intrahepatic biliary dilatation severity detects high-risk primary sclerosing cholangitis","volume":"6","author":"Selvaraj","year":"2022","journal-title":"Hepatol Commun"},{"key":"R15-20260605","article-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"Wells","year":"2018","journal-title":"Medicine"},{"key":"R17-20260605","doi-asserted-by":"crossref","first-page":"h870","DOI":"10.1136\/bmj.h870","article-title":"Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients","volume":"350","author":"Iorio","year":"2015","journal-title":"BMJ"},{"key":"R18-20260605","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s00261-019-02184-z","article-title":"Differentiating pediatric autoimmune liver diseases by quantitative magnetic resonance cholangiopancreatography","volume":"45","author":"Gilligan","year":"2020","journal-title":"Abdom Radiol (NY)"},{"key":"R19-20260605","doi-asserted-by":"crossref","first-page":"1576163","DOI":"10.3389\/fonc.2025.1576163","article-title":"Quantitative MRCP metrics as imaging biomarkers to differentiate benign from malignant bile duct obstructions","volume":"15","author":"Eurboonyanun","year":"2025","journal-title":"Front Oncol"},{"key":"R20-20260605","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.3390\/jcm14155530","article-title":"Exploring the role of MRCP+ for enhancing detection of high-grade strictures in primary sclerosing cholangitis","volume":"14","author":"Franklin","year":"2025","journal-title":"J Clin Med"},{"key":"R21-20260605","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1148\/radiol.10091953","article-title":"Primary sclerosing cholangitis: meta-analysis of diagnostic performance of MR cholangiopancreatography","volume":"256","author":"Dave","year":"2010","journal-title":"Radiology"},{"key":"R22-20260605","doi-asserted-by":"crossref","first-page":"152","DOI":"10.4103\/sjg.SJG_478_18","article-title":"The role of imaging in determining prognosis for primary sclerosing cholangitis: a systematic review","volume":"25","author":"Segal","year":"2019","journal-title":"Saudi J Gastroenterol"},{"key":"R23-20260605","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","article-title":"FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study","volume":"5","author":"Newsome","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R24-20260605","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.jhep.2021.11.012","article-title":"MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis","volume":"76","author":"Noureddin","year":"2022","journal-title":"J Hepatol"},{"key":"R25-20260605","first-page":"613","article-title":"Quantitative MR in paediatric patients with wilson disease: a case series review","volume":"9","author":"Janowski","year":"2022","journal-title":"Children (Basel)"}],"container-title":["Journal of Computer Assisted Tomography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RCT.0000000000001835","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T21:00:29Z","timestamp":1780693229000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RCT.0000000000001835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rct.0000000000001835","relation":{},"ISSN":["1532-3145"],"issn-type":[{"value":"1532-3145","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"assertion":[{"value":"2025-07-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}